# EDGAR Filing Document

**Accession Number:** 0001954488
**File Stem:** 0001213900-26-013306
**Filing Date:** 2026-2
**Character Count:** 2988
**Document Hash:** 81f9c8709e1106f5a028c1f84c99e6e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-013306.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0001213900-26-013306

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260206

**FILED AS OF DATE**: 20260206

**DATE AS OF CHANGE**: 20260206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jyong Biotech Ltd.
- **CENTRAL INDEX KEY:** 0001954488
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42701
- **FILM NUMBER:** 26608158

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
- **STREET 2:** XIZHI DIST.
- **CITY:** NEW TAIPEI CITY
- **PROVINCE COUNTRY:** F5
- **BUSINESS PHONE:** (8862) 27325205

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
- **STREET 2:** XIZHI DIST.
- **CITY:** NEW TAIPEI CITY
- **PROVINCE COUNTRY:** F5

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2026**

**Commission File Number: 001-42701**

**Jyong Biotech Ltd.**

**23F-3, No. 95, Section 1, Xintai 5<sup>th</sup> Road,<br> Xizhi District, New Taipei City,<br> Taiwan, 221** 

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On February 6, 2026, Jyong Biotech Ltd. (the "Company") announced that Wei (Vivi) Zhang has been appointed as the Company's Chief Financial Officer, effective February 6, 2026. Ms. Zhang will be replacing Alfred Ying.

Ms. Wei (Vivi) Zhang is an experienced finance executive with extensive leadership experience in initial public offerings, funds raising and public companies. Most recently, Ms. Wei served as a consultant for a private company in its initial public offering process. Before that, from 2019 to January 2024, she served as Chief Financial Officer and director at Global Mofy AI Limited (f/k/a Global Mofy Metaverse Limited) (listed on Nasdaq since 10/2023: GMM). Ms. Zhang received a bachelor's degree in accounting from the University of South Australia and an MBA degree from the University of Oxford.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Jyong Biotech Ltd.** | **Jyong Biotech Ltd.** |
| Date: February 6, 2026 | By: | /s/ Fu-Feng Kuo |
|  | Name: | Fu-Feng Kuo |
|  | Title: | Chief Executive Officer |

---